Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	
iling Date	2006-10-06
First Named Inventor	Akihiro MATSUURA
Art Unit	
Examiner Name	
Attorney Docket Number	WAKAB83.003APC

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [Date	Name of Pate of cited Docu	entee or Applicant ment	Relev	s,Columns,I ant Passag es Appear		
	1										
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.	_	Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Cite Initial* No		Publication Number Kind Code ¹ Date		Publica Date	name of Patentee of Applicant		Relev	s,Columns,I ant Passag es Appear			
	1										
If you wisl	h to a	dd additional U.S. Publ	shed Ap	plication	citatio	n information p	elease click the Ad	d butto			
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i		Kind Code4	Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columber Rele where Rele Passages of Figures Ap	evant or Relevant	70
	1	WO 98/18657	wo			1998-05-07	Thorsten ALTS				Ø
	2	JP 2002-36405	JP			2002-02-05	Rikizo TANAKA, el	t at.			V
	3	JP 2002-219989	JP			2002-08-06	Kazufumi SHIMIZU al.	J, et			V

U.S.PATENTS

Application Number Filing Date 2006-10-06 Filing Date 2006-10-06 Filing Date 2006-10-06 Filing Date Filing Date Filing Date 2006-10-06 Filing Date Filing Date Filing Date Filing Date Filing Date Althorous MATSUURA Art Unit Examiner Name Attorney Docket Number WAMA983.003APC

	4	JP 2	003-208183	JP		2003-07-25	M. IMAMURA, e	t al_			V
If you wis	h to a	dd add	litional Foreign I	Patent Document	citation	information pl	ease click the Ad	dd butto	n Add		
	NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city andior country where published.						Τs				
	1										
If you wish to add additional non-patent literature document citation information please click the Add button Add											
	EXAMINER SIGNATURE										
Examiner	Signa	ture					Date Consi	dered			

See Kint Codes of USPTO Patent Documents at InventUSPTO.GDV or MPEP 901.04. Enter office that issued the document, by the Nov-letter option Standard 513.) For Laplanese patent focuments, the inclusion of the parent of the Improver protects the sent number the patent document. A focument by the appropriate symbols as enducated on the document under WIPO Standard 51.16 if possible. Spapicant is to place a check mark here if English language translation is attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number Filing Date 2006-10-06 Filing Date 2006-10-06 Filing Date 2006-10-06 Filing Date Filing Date Filing Date 2006-10-06 Filing Date Filing Date 2006-10-06 Filing Date 2

CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/t1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart to reign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFP 1 97 and 1 98 to make the appropriate selection(s):

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/KOA43315/	Date (YYYY-MM-DD)	2006-10-06
Name/Print	Katsuhiro Arai	Registration Number	43315

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by 35 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, u.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.32.11.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.32.213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.